Skip to main content

Home/ Dr. Goodyear/ Group items tagged tamoxifen

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Nathan Goodyear

BMC Cancer | Full text | Estrogen receptor alpha/beta ratio and estrogen rece... - 0 views

www.biomedcentral.com/...425

breast cancer ER alpha ER-alpha ER beta ER-beta SERM tamoxifen anastrazole women hormone hormones female

shared by Nathan Goodyear on 08 Oct 14 - No Cached
  • 75% of human BCs express estrogen receptors (ERs)
  • Nathan Goodyear on 08 Oct 14
     
    ER beta expression and the ratio of ER alpha/ER beta is important in prognosis and effectiveness of SERM therapy like tamoxifen.  This study looked at the aromatase inhibitor anastrazole as well.
Nathan Goodyear

Effect of dietary GLA+/−tamoxifen on the growth, ER expression and fatty acid... - 0 views

onlinelibrary.wiley.com/...pdf

GLA breast cancer estrogen receptor positive tamoxifen

shared by Nathan Goodyear on 11 Feb 11 - No Cached
  • Nathan Goodyear on 11 Feb 11
     
    GLA enhances the effectiveness of tamoxifen in the treatment of ER + breast cancer
Nathan Goodyear

Quercetin and tamoxifen sensitize human melanoma cells to hyperthermia. - PubMed - NCBI - 1 views

www.ncbi.nlm.nih.gov/...11595883

quercetin cancer melanoma hyperthermia tamoxifen

shared by Nathan Goodyear on 23 Feb 19 - No Cached
  • Nathan Goodyear on 23 Feb 19
     
    Quercetin and tamoxifen were shown to reduce HSP27 expression when used in conjunction with severe hyperthermia (42.5 C)
Nathan Goodyear

Dichloroacetate potentiates tamoxifen-induced cell death in breast cancer cells via dow... - 0 views

www.ncbi.nlm.nih.gov/...PMC5312350

DCA Dichloroacetate breast cancer tamoxifen

shared by Nathan Goodyear on 17 Jul 19 - No Cached
  • Nathan Goodyear on 17 Jul 19
     
    DCA increased breast cancer cell sensitivity to tamoxifen
Nathan Goodyear

Effect of artesunate on apoptosis and autophagy in tamoxifen resistant breast cancer ce... - 0 views

tcr.amegroups.com/...html

tamoxifen artesunate breast cancer

shared by Nathan Goodyear on 07 May 20 - No Cached
  • Nathan Goodyear on 07 May 20
     
    Artesunate effective in Tamoxifen resistant breast cancer cells lines via reduction in Bcl-2, survivin, and increase in Caspase-7.
Nathan Goodyear

Vitamin C suppresses cell death in MCF‐7 human breast cancer cells induced by... - 1 views

onlinelibrary.wiley.com/...jcmm.12188

tamoxifen low dose vitamin C breast cancer vitamin C

shared by Nathan Goodyear on 14 Aug 22 - No Cached
frankbkelly liked it
  • Nathan Goodyear on 14 Aug 22
     
    Low dose c/w oral dosing is antioxidative and here counters Tamoxifen breast cancer effects. Miss the point of vitamin C when dose correctly!
Nathan Goodyear

Estradiol, Tamoxifen, and Flaxseed A... [J Clin Endocrinol Metab. 2012] - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...22930784

diet estradiol flaxseed breast cancer Ca inflammation cytokines IL-1alpha IL-1Beta IL-1Ra

shared by Nathan Goodyear on 17 Nov 12 - No Cached
  • Nathan Goodyear on 17 Nov 12
     
    Tamoxifen and more importantly, flaxseed increases endogenous IL-1Ra that is a known inhibitor of the pro-inflammatory cytokines IL-1alpha and IL-1beta. These pro-inflammatory cytokines are associated with breast cancer.  Conclusion: diet modification can effect inflammatory cytokines associated with breast cancer.  This should be explored as true preventative therapies for women. This study also found a positive association with estradiol and IL-1Beta in breast tissue and SC fat; inversely associated with IL-Ra in the breast.
Nathan Goodyear

Expressions of vascular endothelial growth factor an... [Thyroid. 2010] - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...20017619

estrogen SERMs tamoxifen raloxifene thyroid VEGF

shared by Nathan Goodyear on 16 Nov 11 - No Cached
  • Nathan Goodyear on 16 Nov 11
     
    estrogen and SERMS (tamoxifen, raloxifene) shown to stimulate growth of thyroid cells via regulation of vascularization.  Think about the impact of the estrogen on other cells and tissue in the body.
Nathan Goodyear

Weight gain after primary surgery fo... [Breast Cancer Res Treat. 1992] - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...1391977

tamoxifen weight weight gain women hormones hormone cancer breast breast cancer pre-menopause Postmenopause

shared by Nathan Goodyear on 08 Oct 14 - No Cached
  • Nathan Goodyear on 08 Oct 14
     
    The increased weight with tamoxifen is seen premenopausal women, but less with postmenopausal women.
Nathan Goodyear

Weight gain and recovery of pre-cancer weight after breast cancer treatments: evidence ... - 0 views

www.ncbi.nlm.nih.gov/...17123151

chemotherapy cancer obesity weight gain

shared by Nathan Goodyear on 14 Jun 16 - No Cached
  • Nathan Goodyear on 14 Jun 16
     
    chemotherapy associated with significant weight gain with low rate of return to pre-chemo weight.  Tamoxifen was not associated with increased weight gain.
Nathan Goodyear

Estrogen Receptor β Expression Is Associated with Tamoxifen Response in ERα-N... - 0 views

clincancerres.aacrjournals.org/...1987.long

ER beta ER-beta estrogen receptors breast cancer tamoxifen estrogen receptor estrogen receptor women hormone hormones

shared by Nathan Goodyear on 08 Oct 14 - No Cached
  • Nathan Goodyear on 08 Oct 14
     
    Increased survival in those with ER beta + and ER alpha -.  Early relapse was associated with lack of ER beta expression.  ER beta is transcribed from a different genomic location than ER alpha.  
Nathan Goodyear

Selective Estrogen Receptor Modulators and Phytoestrogens - 0 views

www.ncbi.nlm.nih.gov/...PMC2587438

phytoestrogens selective estrogen receptor modulators cancer SERMs

shared by Nathan Goodyear on 31 Jul 20 - No Cached
  • Nathan Goodyear on 31 Jul 20
     
    Nice review of natural SERMs as natural alternatives to Tamoxifen
Nathan Goodyear

The Androgen 5α-Dihydrotestosterone and Its Metabolite 5α-Androstan-3β, 17β-D... - 0 views

www.jneurosci.org/...1448.full

DHT 3 beta androstanediol androgens Hypothalamus HPA hormones stress

shared by Nathan Goodyear on 15 Jul 15 - No Cached
  • Sex steroid hormones are primarily responsible for sex difference in adult HPA function; androgens inhibit whereas estrogens enhance HPA axis activation after a stressor
  • the PVN contains relatively high levels of AR (Bingaman et al., 1994; Zhou et al., 1994) and ERβ (Alves et al., 1998; Hrabovszky et al., 1998; Somponpun and Sladek, 2003) but is essentially devoid of ERα
  • the nonaromatizable androgen DHT and the nonselective ER ligand E2 influence HPA reactivity by acting on neurons within or surrounding the PVN
  • ...9 more annotations...
  • inhibitory action of DHT is detectable at both the level of hormone secretion as well as PVN c-fos mRNA expression
  • the inhibition can be mimicked by the DHT metabolite 3β-diol and by the subtype selective ERβ agonist DPN
  • E2 acts to enhance HPA reactivity
  • the ability of the ER antagonist tamoxifen, but not the AR antagonist flutamide, to block the inhibitory actions of DHT, speaks to the intracellular mechanism by which this inhibitory signal might be transduced.
    • Nathan Goodyear
      Nathan Goodyear on 15 Jul 15
       
      that is because the interaction with the DHT metabolite is not with the AR, but with the ER-beta.
  • the DHT metabolite 3β-diol and the ERβ-subtype-selective agonist DPN suppressed ACTH, corticosterone, and c-fos mRNA responses to restraint stress in a manner similar to DHT
  • metabolism of DHT to 3β-diol and subsequent binding to ERβ can be inhibitory to HPA reactivity, and this is one possible mechanism for the action of DHT.
  • Our data also suggest that E2 enhances the reactivity of the HPA axis to stress by acting on or near neurons of the PVN
  • the actions of E2 appear to be through an ERα-dependent mechanism
  • these studies suggest that ERβ, within the male hypothalamus, acts to inhibit the HPA axis and that the inhibitory effects of DHT may be, at least in part, via its intracellular conversion to 3β-diol and subsequent binding to ERβ
  • Nathan Goodyear on 15 Jul 15
     
    DHT metabolites: particularly 3beta-androstanediol inhibit HPA axis through ER-beta.
Nathan Goodyear

Estrogen synthesis in human colon cancer epithelial cells | Alternative Medicine Review... - 0 views

findarticles.com/...ai_65068489

colon cancer estrogen aromatase quercetin

shared by Nathan Goodyear on 09 Feb 11 - No Cached
  • These findings demonstrate for the first time that colorectal adenocarcinoma cell lines express aromatase. Interestingly, the enzyme activity was inhibited by quercetin, one major dietary flavonoid, by tamoxifen, a hormonal therapeutic agent for breast cancer, and by raloxifene, used in the prevention of postmenopausal osteoporosis.
  • Nathan Goodyear on 09 Feb 11
     
    colon cancer cells regulated by Estrogen through aromatase activity
Nathan Goodyear

Lipoprotein(a) as a cardiovascular risk factor: current status - 0 views

eurheartj.oxfordjournals.org/...2844.full

cardiovascular risk disease lipoprotein a Lp(a) LDL lipoprotein(a) niacin

shared by Nathan Goodyear on 06 Aug 14 - No Cached
  • Lipoprotein(a) is a plasma lipoprotein consisting of a cholesterol-rich LDL particle with one molecule of apolipoprotein B100 and an additional protein, apolipoprotein(a)
  • Elevated Lp(a) levels can potentially increase the risk of CVD (i) via prothrombotic/anti-fibrinolytic effects as apolipoprotein(a) possesses structural homology with plasminogen and plasmin but has no fibrinolytic activity and (ii) via accelerated atherogenesis as a result of intimal deposition of Lp(a) cholesterol, or both
  • evidence suggests that apolipoprotein(a) adducts extracellularly and covalently to apolipoprotein B100-containing lipoproteins, predominantly LDL
  • ...2 more annotations...
  • Lp(a) is relatively refractory to both lifestyle and drug intervention.
  • Other agents reported to decrease Lp(a) to a minor degree (<10%) include aspirin, l-carnitine, ascorbic acid combined with l-lysine, calcium antagonists, angiotensin-converting enzyme inhibitors, androgens, oestrogen, and its replacements (e.g. tibolone), anti-estrogens (e.g. tamoxifen), and thyroxine replacement in hypothyroid subjects
  • Nathan Goodyear on 06 Aug 14
     
    full article on the previously posted abstract on Lp(a).  
Nathan Goodyear

How We Read Oncologic FDG PET/CT | Cancer Imaging | Full Text - 0 views

cancerimagingjournal.biomedcentral.com/...s40644-016-0091-3

PET_CT PET scan CT cancer

shared by Nathan Goodyear on 20 Feb 18 - No Cached
  • In early PET literature focusing on analysis of solitary pulmonary nodules, some researchers defined malignancy based on a SUVmax threshold of greater than 2.5
  • We contend that SUV analysis has virtually no role in this setting.
  • tumours grow as spheres, whereas inflammatory processes are typically linear
  • ...35 more annotations...
  • Far more important than the SUVmax is the pattern rather than intensity of metabolic abnormality and the correlative CT findings
  • Descriptively, we define SUV < 5 as “low intensity”, 5–10 as “moderate”, 10–15 as “intense” and >15 as “very intense”
  • Evolving literature suggests that intensity of uptake is an independent prognostic factor and in some tumour subtypes superior to histopathologic characterisation.
  • aerobic glycolysis
  • Our practice of thresholding the grey and colour scale to liver as detailed above results in similar image intensity to a fixed upper SUV threshold of 8 to 10
  • The advantage of using the liver as a reference tissue is also aided by this organ having rather low variability in metabolic activity
  • When the liver is abnormal and cannot be used as a reference organ, we use the default SUV setting of an upper SUV threshold of 8
  • One of the most challenging aspects of oncologic FDG PET/CT review, however, is to recognise all the patterns of metabolic activity that are not malignant and which consequently confound interpretation
  • Many benign and inflammatory processes are also associated with high glycolytic activity
  • Future articles in the “How I Read” series will address the specific details of reading PET/CT in various cancers
  • The intensity of uptake in metastases usually parallels that in the primary site of disease
  • For example, discordant low-grade activity in an enlarged lymph node in the setting of intense uptake in the primary tumour suggests it is unlikely malignant and more likely inflammatory or reactive
  • By CT criteria the enlarged node is ‘pathologic’ but the discordantly low metabolic signature further characterises this is as non-malignant since such a node is not subject to partial volume effects and therefore the intensity of uptake should be similar to the primary site
  • The exception is when the lymph node is centrally necrotic as a small rim of viable tumour is subject to partial volume effects with expectant lower intensity of uptake; integrating the CT morphology is therefore critical to reaching an accurate interpretation
  • Small nodes that are visualised on PET are conversely much more likely to be metastatic as such nodes are subject to partial volume effects.
  • The exception to this rule is tumours with a propensity for tumour heterogeneity at different sites
  • The combination of FDG and a more specific tracer, which visualises the well-differentiated disease can be very useful to characterise this phenomenon
  • “metabolic signature”
  • For the majority of malignant processes, the intensity of metabolic abnormality correlates with degree of aggressiveness or proliferative rate.
  • a negative PET/CT study in a patient with biopsy proven malignancy would be considered false-negative
  • Warburg effect
  • There, however, are a significant minority of tumours that utilise substrates other glucose such as glutamine or fatty acids as a source of the carbon atoms required for growth and proliferation
  • This includes a subset of diffuse gastric adenocarcinomas, signet cell colonic adenocarcinomas and some sarcomas, particularly liposarcoma
  • There may be a role for other radiotracers such as fluorothymidine (FLT) or amino acid substrates in this setting.
  • Some tumours harbour mutations that result in defective aerobic mitochondrial energy metabolism, effectively simulating the Warburg effect
  • patients with hereditary paraganglioma and pheochromocytoma highlight this phenomenon
  • These have intense uptake on FDG PET/CT despite often having low proliferative rate.
  • Uterine fibroids, hepatic adenomas, fibroadenomas of the breast and desmoid tumours are benign or relatively benign lesions that can have quite high FDG-avidity.
  • Metabolic activity switches off rapidly following initiation of therapy
  • Common examples where patients have commenced active therapy but the referrer is requesting “staging” includes hormonal therapy (eg. tamoxifen) in breast cancer, oral capecitabine in colorectal cancer or high dose steroids in Hodgkin’s lymphoma
  • It is therefore critical to perform PET staging before commencement of anti-tumour therapy
  • The potential advantage of routine diagnostic CT is improved anatomic localisation and definition
  • Without intravenous contrast, additional identification of typical oncologic complications such as pulmonary embolism or venous thrombosis cannot be identified
  • If the study is performed as an “interim” restaging study after commencement of therapy but before completion, in order to reach a valid or clinically useful conclusion findings must be interpreted in the context of known changes that occur at a specific timing and type of therapy
  • The most well studied use of interim PET is in Hodgkin’s lymphoma where repeat PET after two cycles of ABVD-chemotherapy provides powerful prognostic information and may improve outcomes by enabling early change of management
  • Nathan Goodyear on 20 Feb 18
     
    good read on the PET/CT scan reading.  They mention that tumors are spheres and inflammation is linear, yet inflammation coexists with cancer; hard to simply delineate these on simple terms. I do agree aon the metabolic signature of the PET/CT scan
1 - 20 of 20
Showing 20▼ items per page